MarketPeel
Insider Trading Intelligence
MK

Michael King

SABS
CHIEF FINANCIAL OFFICER · SAB BIOTHERAPEUTICS, INC. · CIK 0001998530
FILING MIX · LIFETIME100%/0%
BUYS
3
SELLS
0
TOTAL VALUE
$4.5K
COMPANIES
1
ACTIVE SINCE
Oct 2023
HOLDINGS NOW
115,000
AVG SELL PX
TRADE KIND
SHOWING 3 / 3
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Michael King, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-8.64%+0.40%-9.04%-9.04%
14d1+0.00%-19.75%+3.42%-23.17%-23.17%
30d1+0.00%-29.27%+4.57%-33.84%-33.84%
60d1+0.00%-38.37%+8.08%-46.45%-46.45%
90d1+0.00%-56.58%+11.37%-67.96%-67.96%
180d1+0.00%-72.02%+16.92%-88.93%-88.93%
1y1+0.00%-69.96%+33.81%-103.77%-103.77%
2y1+0.00%-59.36%+52.73%-112.09%-112.09%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SABS · 115,000 shares · as of Feb 21, 2024
0212,500425,000637,500850,0002024SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2024
FLOW · 3 buys / 0 sellsCOVERAGE · 2 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
115,000115,000Feb 21, 2024Feb 23, 2024View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASE
CHIEF FINANCIAL OFFICER
5,000$0.90$4.5K5,000Nov 30, 2023Nov 30, 2023View →
SABS
SAB BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
850,000850,000Oct 30, 2023Nov 3, 2023View →
Other insiders · SABS
Loading peer insiders…
About this filer
CIK 0001998530
ROLE
CHIEF FINANCIAL OFFICER
PRIMARY
SABS
COMPANIES
1
ACTIVE SINCE
Oct 2023
MARKETPEEL · /INSIDER/0001998530DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback